25 Nov 2019 --- Cannabidiol (CBD) obtained by “synthetic means” is now excluded from the US Controlled Substance Act (CSA) regulatory controls, as long as it contains no more than 0.3 percent tetrahydrocannabinol (THC). This is according to a letter from the US Drug Enforcement Agency (DEA) received by Purisys, a producer of major cannabinoids relevant to pharmaceutical and consumer products, as well as degradants, metabolites and analytical reference standards. Over 30 other cannabinoids have also been descheduled from Schedule I of the CSA. The company expects that this will encourage research and, based on sound clinical and safety studies, create a broader path for cannabinoids’ use in pharmaceutical and consumer products.
